Disease-specific outcomes of Radical Prostatectomies in Northern Norway; A case for the impact of perineural infiltration and postoperative PSA-doubling time

BMC Urology

Volumn 14, Issue 1, 2014, Pages

  Andersen, Sigve ^a,b   Richardsen, Elin ^a,b   Nordby, Yngve ^a,b   Ness, Nora ^a   Størkersen, Øystein ^c   Al Shibli, Khalid ^d   Donnem, Tom ^a,b   Bertilsson, Helena ^c,e   Busund, Lill Tove ^a,b   Angelsen, Anders ^c,e   Bremnes, Roy M ^a,b  

^a UNIVERSITY OF TROMSØ   (Norway)

^b UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^c TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^d NORDLAND HOSPITAL   (Norway)

^e NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BIOCHEMICAL FAILURE FREE SURVIVAL; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EVENT FREE SURVIVAL; FAILURE FREE SURVIVAL; FOLLOW UP; GLEASON SCORE; HUMAN; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); NORWAY; PERINEURAL INFILTRATION; PERINEURAL INVASION; POSTOPERATIVE PERIOD; PROSTATE CANCER; PROSTATECTOMY; RETROSPECTIVE STUDY; TIME; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR VOLUME;

ADULT; AGED; HUMANS; MALE; MIDDLE AGED; NORWAY; PERIPHERAL NERVOUS SYSTEM NEOPLASMS; POSTOPERATIVE CARE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84902052886     PISSN: None     EISSN: 14712490     Source Type: Journal    
DOI: 10.1186/1471-2490-14-49     Document Type: Article

References (64)

1. Cancer registery of Norway, Cancer in Norway 2010-cancer incidence, mortality, survival and prevalence in Norway Oslo: Cancer registery of Norway 2012 Ref Type: Report. http://www.kreftregisteret.no
2. Curative treatment of prostatic cancer in Norway in 1998 and 2001. Kvale R, Skarre E, Tonne A, Kyrdalen AE, Norstein J, Angelsen A, Wahlqvist R, Fossa SD, Tidsskr Nor Laegeforen 2006 126 7 912 916 16554883
3. International variation in prostate cancer incidence and mortality rates. Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, Bray F, Eur Urol 2012 61 6 1079 1092 10.1016/j.eururo.2012.02.054 22424666
4. Regional trends in prostate cancer incidence, treatment with curative intent and mortality in Norway 1980-2007. Kvale R, Moller B, Angelsen A, Dahl O, Fossa SD, Halvorsen OJ, Hoem L, Solberg A, Wahlqvist R, Bray F, Cancer Epidemiol 2010 34 4 359 367 10.1016/j.canep.2010.04.017 20627840
5. Radical prostatectomy versus observation for localized prostate cancer. Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, Gingrich JR, Wei JT, Gilhooly P, Grob BM, Nsouli I, Iyer P, Cartagena R, Snider G, Roehrborn C, Sharifi R, Blank W, Pandya P, Andriole GL, Culkin D, Wheeler T, N Engl J Med 2012 367 3 203 213 10.1056/NEJMoa1113162 22808955
6. Individualized estimation of the benefit of radical prostatectomy from the scandinavian prostate cancer group randomized trial. Vickers A, Bennette C, Steineck G, Adami HO, Johansson JE, Bill-Axelson A, Palmgren J, Garmo H, Holmberg L, Eur Urol 2012 62 2 204 209 10.1016/j.eururo.2012.04.024 22541389
7. Radical prostatectomy versus watchful waiting in early prostate cancer. Bill-Axelson A, Holmberg L, Ruutu M, Garmo H, Stark JR, Busch C, Nordling S, Haggman M, Andersson SO, Bratell S, Spangberg A, Palmgren J, Steineck G, Adami HO, Johansson JE, N Engl J Med 2011 364 18 1708 1717 10.1056/NEJMoa1011967 21542742
8. Survival after radical prostatectomy for clinically localised prostate cancer: a population-based study. Roder MA, Brasso K, Christensen IJ, Johansen J, Langkilde NC, Hvarness H, Carlsson S, Jakobsen H, Borre M, Iversen P, BJU Int 2014 113 4 541 547 10.1111/bju.12065 23495721
9. Radical prostatectomy in Austria from 1992 to 2009: an updated nationwide analysis of 33,580 cases. Wehrberger C, Berger I, Willinger M, Madersbacher S, J Urol 2012 187 5 1626 1631 10.1016/j.juro.2011.12.080 22425090
10. Increasing use of radical prostatectomy for nonlethal prostate cancer in Sweden. Etzioni R, Mucci L, Chen S, Johansson JE, Fall K, Adami HO, Clin Cancer Res 2012 18 24 6742 6747 10.1158/1078-0432.CCR-12-1537 22927485
11. Predictive models before and after radical prostatectomy. Capitanio U, Briganti A, Gallina A, Suardi N, Karakiewicz PI, Montorsi F, Scattoni V, Prostate 2010 70 12 1371 1378 20623635
12. Use of classical and novel biomarkers as prognostic risk factors for localised prostate cancer: a systematic review. Sutcliffe P, Hummel S, Simpson E, Young T, Rees A, Wilkinson A, Hamdy F, Clarke N, Staffurth J, Health Technol Assess 2009 13 5 9211-9313.
13. Nomograms for staging, prognosis, and predicting treatment outcomes. Touijer K, Scardino PT, Cancer 2009 115 13 Suppl 3107 3111 19544538
14. Prognostic significance of lymphovascular invasion in radical prostatectomy specimens. Ng J, Mahmud A, Bass B, Brundage M, BJU Int 2012 110 10 1507 1514 10.1111/j.1464-410X.2012.11115.x 22502733
15. Predicting tumor volume in radical prostatectomy specimens from patients with prostate cancer. Eichelberger LE, Koch MO, Daggy JK, Ulbright TM, Eble JN, Cheng L, Am J Clin Pathol 2003 120 3 386 391 10.1309/82U1089XLQGKMMN1 14502802
16. Prognostic significance of tumor volume in radical prostatectomy and needle biopsy specimens. Epstein JI, J Urol 2011 186 3 790 797 10.1016/j.juro.2011.02.2695 21788055
17. Impact of a tertiary Gleason pattern 4 or 5 on clinical failure and mortality after radical prostatectomy for clinically localised prostate cancer. Servoll E, Saeter T, Vlatkovic L, Lund T, Nesland J, Waaler G, Axcrona K, Beisland HO, BJU Int 2012 109 10 1489 1494 10.1111/j.1464-410X.2011.10583.x 21933333
18. Assessing and treating patients with increasing prostate specific antigen following radical prostatectomy. Sandler HM, Eisenberger MA, J Urol 2007 178 3 Pt 2 20 S24 17644123
19. Rising PSA in nonmetastatic prostate cancer. Moul JW, Banez LL, Freedland SJ, Oncology (Williston Park) 2007 21 12 1436 1445 18077992
20. Current controversies in the management of biochemical failure in prostate cancer. Bruce JY, Lang JM, McNeel DG, Liu G, Clin Adv Hematol Oncol 2012 10 11 716 722 23271258
21. The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up. Antonarakis ES, Feng Z, Trock BJ, Humphreys EB, Carducci MA, Partin AW, Walsh PC, Eisenberger MA, BJU Int 2012 109 1 32 39 10.1111/j.1464-410X.2011. 10422.x 21777360
22. Time to detectable metastatic disease in patients with rising prostate-specific antigen values following surgery or radiation therapy. Slovin SF, Wilton AS, Heller G, Scher HI, Clin Cancer Res 2005 11 24 Pt 1 8669 8673 16361552
23. Predictors of metastatic disease in men with biochemical failure following radical prostatectomy. Okotie OT, Aronson WJ, Wieder JA, Liao Y, Dorey F, DeKERNION JB, Freedland SJ, J Urol 2004 171 6 Pt 1 2260 2264 15126798
24. Natural history of progression after PSA elevation following radical prostatectomy. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC, JAMA 1999 281 17 1591 1597 10.1001/jama.281.17.1591 10235151
25. Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, Partin AW, J Clin Oncol 2007 25 13 1765 1771 10.1200/JCO.2006.08.0572 17470867
26. Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. Ross AE, Loeb S, Landis P, Partin AW, Epstein JI, Kettermann A, Feng Z, Carter HB, Walsh PC, J Clin Oncol 2010 28 17 2810 2816 10.1200/JCO.2009.25.7311 20439642
27. Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy. O'Brien MF, Cronin AM, Fearn PA, Smith B, Stasi J, Guillonneau B, Scardino PT, Eastham JA, Vickers AJ, Lilja H, J Clin Oncol 2009 27 22 3591 3597 10.1200/JCO.2008.19. 9794 19506163
28. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. Stephenson AJ, Kattan MW, Eastham JA, Dotan ZA, Bianco FJ Jr, Lilja H, Scardino PT, J Clin Oncol 2006 24 24 3973 3978 10.1200/JCO.2005.04.0756 16921049
29. Staging of prostate cancer. Cheng L, Montironi R, Bostwick DG, Lopez-Beltran A, Berney DM, Histopathology 2012 60 1 87 117 10.1111/j.1365-2559. 2011.04025.x 22212080
30. Impact of positive apical surgical margins on likelihood of biochemical recurrence after radical prostatectomy. Kordan Y, Salem S, Chang SS, Clark PE, Cookson MS, Davis R, Herrell SD, Baumgartner R, Phillips S, Smith JA Jr, Barocas DA, J Urol 2009 182 6 2695 2701 10.1016/j.juro.2009.08.054 19836759
31. Impact of positive surgical margins after radical prostatectomy. Chang SS, Cookson MS, Urology 2006 68 2 249 252 10.1016/j.urology.2006.03.053 16904428
32. Clinicopathological predictors of systemic progression and prostate cancer mortality in patients with a positive surgical margin at radical prostatectomy. Boorjian SA, Tollefson MK, Rangel LJ, Bergstralh EJ, Karnes RJ, Prostate Cancer Prostatic Dis 2012 15 1 56 62 10.1038/pcan.2011.36 21808286
33. The 2005 International Society of Urological Pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL, Am J Surg Pathol 2005 29 9 1228 1242 10.1097/01.pas.0000173646.99337.b1 16096414
34. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC, Urol Clin North Am 2001 28 3 555 565 10.1016/S0094-0143(05)70163-4 11590814
35. The effect of Gleason score on the predictive value of prostate-specific antigen doubling time. Tollefson MK, Blute ML, Rangel LJ, Bergstralh EJ, Boorjian SA, Karnes RJ, BJU Int 2010 105 10 1381 1385 19863524
36. Predicting 15-year prostate cancer specific mortality after radical prostatectomy. Eggener SE, Scardino PT, Walsh PC, Han M, Partin AW, Trock BJ, Feng Z, Wood DP, Eastham JA, Yossepowitch O, Rabah DM, Kattan MW, Yu C, Klein EA, Stephenson AJ, J Urol 2011 185 3 869 875 10.1016/j.juro.2010.10.057 21239008
37. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, Partin AW, JAMA 2005 294 4 433 439 10.1001/jama.294.4.433 16046649
38. Predictors of metastatic disease in men with biochemical failure following radical prostatectomy. Okotie OT, Aronson WJ, Wieder JA, Liao Y, Dorey F, DeKERNION JB, Freedland SJ, J Urol 2004 171 6 Pt 1 2260 2264 15126798
39. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. Trock BJ, Han M, Freedland SJ, Humphreys EB, DeWeese TL, Partin AW, Walsh PC, JAMA 2008 299 23 2760 2769 10.1001/jama.299.23.2760 18560003
40. Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH, J Urol 2004 172 5 Pt 2 42 S46 15535442
41. Risk stratification after biochemical failure following curative treatment of locally advanced prostate cancer: data from the TROG 96.01 Trial. Prostate. Steigler A, Denham JW, Lamb DS, Spry NA, Joseph D, Matthews J, Atkinson C, Turner S, North J, Christie D, Tai KH, Wynne C, Cancer 2012 2012 814724
42. The contemporary concept of significant versus insignificant prostate cancer. Ploussard G, Epstein JI, Montironi R, Carroll PR, Wirth M, Grimm MO, Bjartell AS, Montorsi F, Freedland SJ, Erbersdobler A, van der Kwast TH, Eur Urol 2011 60 2 291 303 10.1016/j.eururo.2011.05.006 21601982
43. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ, J Urol 2004 172 3 910 914 10.1097/01.ju.0000134888.22332.bb 15310996
44. Stratification of patient risk based on prostate-specific antigen doubling time after radical retropubic prostatectomy. Tollefson MK, Slezak JM, Leibovich BC, Zincke H, Blute ML, Mayo Clin Proc 2007 82 4 422 427 10.4065/82.4.422 17418069
45. Quantification of extraprostatic perineural spread and its prognostic value in pT3a pN0 M0 R0 prostate cancer patients. Aumayr K, Breitegger M, Mazal PR, Koller A, Marberger M, Susani M, Haitel A, Prostate 2011 71 16 1790 1795 10.1002/pros.21396 21563191
46. Perineural invasion is a prognostic factor for biochemical failure after radical prostatectomy. Jeon HG, Bae J, Yi JS, Hwang IS, Lee SE, Lee E, Int J Urol 2009 16 8 682 686 10.1111/j.1442-2042.2009.02331.x 19602004
47. Risk-stratified survival rates and predictors of biochemical recurrence after radical prostatectomy in a Nara, Japan, cohort study. Tanaka N, Fujimoto K, Hirayama A, Torimoto K, Okajima E, Tanaka M, Miyake M, Shimada K, Konishi N, Hirao Y, Int J Clin Oncol 2011 16 5 553 559 10.1007/s10147-011-0226-2 21437569
48. Correlation of perineural invasion on radical prostatectomy specimens with other pathologic prognostic factors and PSA failure. Ozcan F, Eur Urol 2001 40 3 308 312 10.1159/000049791 11684847
49. Prediction of perineural invasion and its prognostic value in patients with prostate cancer. Lee JT, Lee S, Yun CJ, Jeon BJ, Kim JM, Ha HK, Lee W, Chung MK, Korean J Urol 2010 51 11 745 751 10.4111/kju.2010.51.11.745 21165193
50. Prognostic role of perineural invasion in 239 consecutive patients with pathologically organ-confined prostate cancer. Masieri L, Lanciotti M, Nesi G, Lanzi F, Tosi N, Minervini A, Lapini A, Carini M, Serni S, Urol Int 2010 85 4 396 400 10.1159/000315491 20516669
51. Parameters of perineural invasion in radical prostatectomy specimens lack prognostic significance. Merrilees AD, Bethwaite PB, Russell GL, Robinson RG, Delahunt B, Mod Pathol 2008 21 9 1095 1100 10.1038/modpathol.2008.81 18500264
52. Significance of perineural invasion, lymphovascular invasion, and high-grade prostatic intraepithelial neoplasia in robot-assisted laparoscopic radical prostatectomy. Jung JH, Lee JW, Arkoncel FR, Cho NH, Yusoff NA, Kim KJ, Song JM, Kim SJ, Rha KH, Ann Surg Oncol 2011 18 13 3828 3832 10.1245/s10434-011-1790-4 21660497
53. Percent prostate needle biopsy tissue with cancer is more predictive of biochemical failure or adverse pathology after radical prostatectomy than prostate specific antigen or Gleason score. Freedland SJ, Csathy GS, Dorey F, Aronson WJ, J Urol 2002 167 2 Pt 1 516 520 11792909
54. Perineural invasion as a predictor of biochemical outcome following radical prostatectomy for select men with clinically localized prostate cancer. D'Amico AV, Wu Y, Chen MH, Nash M, Renshaw AA, Richie JP, J Urol 2001 165 1 126 129 10.1097/00005392-200101000-00031 11125380
55. Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. Partin AW, Pound CR, Clemens JQ, Epstein JI, Walsh PC, Urol Clin North Am 1993 20 4 713 725 7505980
56. Perineural invasion predicts increased recurrence, metastasis, and death from prostate cancer following treatment with dose-escalated radiation therapy. Feng FY, Qian Y, Stenmark MH, Halverson S, Blas K, Vance S, Sandler HM, Hamstra DA, Int J Radiat Oncol Biol Phys 2011 81 4 361 e367 10.1016/j.ijrobp.2011.04.048 21820250
57. The impact of positive surgical margins on mortality following radical prostatectomy during the prostate specific antigen era. Boorjian SA, Karnes RJ, Crispen PL, Carlson RE, Rangel LJ, Bergstralh EJ, Blute ML, J Urol 2010 183 3 1003 1009 10.1016/j.juro.2009.11.039 20092854
58. Radical prostatectomy: hospital volumes and surgical volumes-does practice make perfect? Urbanek C, Turpen R, Rosser CJ, BMC Surg 2009 9 10 10.1186/1471-2482-9-10 19500401
59. Screening with low PSA cutoff values results in low rates of positive surgical margins in radical prostatectomy specimens. Berger AP, Volgger H, Rogatsch H, Strohmeyer D, Steiner H, Klocker H, Bartsch G, Horninger W, Prostate 2002 53 3 241 245 10.1002/pros.10167 12386925
60. Variations among individual surgeons in the rate of positive surgical margins in radical prostatectomy specimens. Eastham JA, Kattan MW, Riedel E, Begg CB, Wheeler TM, Gerigk C, Gonen M, Reuter V, Scardino PT, J Urol 2003 170 6 Pt 1 2292 2295 14634399
61. Anatomic site-specific positive margins in organ-confined prostate cancer and its impact on outcome after radical prostatectomy. Blute ML, Bostwick DG, Bergstralh EJ, Slezak JM, Martin SK, Amling CL, Zincke H, Urology 1997 50 5 733 739 10.1016/S0090-4295(97)00450-0 9372884
62. Positive surgical margins with radical retropubic prostatectomy: anatomic site-specific pathologic analysis and impact on prognosis. Obek C, Sadek S, Lai S, Civantos F, Rubinowicz D, Soloway MS, Urology 1999 54 4 682 688 10.1016/S0090-4295(99)00204-6 10510928
63. Site of positive surgical margins influences biochemical recurrence after radical prostatectomy. Godoy G, Tareen BU, Lepor H, BJU Int 2009 104 11 1610 1614 10.1111/j.1464-410X.2009.08688.x 19549257
64. First Danish single-institution experience with radical prostatectomy: impact of surgical margins on biochemical outcome. Vrang ML, Roder MA, Vainer B, Christensen IJ, Gruschy L, Brasso K, Iversen P, Scand J Urol Nephrol 2012 46 3 172 179 10.3109/00365599.2011.644860 22320899